Now there’s a new kid on the block called tofacitinib (Xeljanz). Relatively new, that is. Xeljanz, which received Food and Drug Administration (FDA) approval in 2012, is becoming a more and more popular drug option for RA. It is poised to become a profitable one, too. It is already positioned to grab a big piece of the rheumatoid arthritis drug market, predicted to grow to $18.2 billion by 2023.

Xeljanz Ideal for Patients Who Can’t Take Methotrexate

As with any medication, the decision to use Xeljanz or not is up to the rheumatologist and their patient. Every patient is unique; every case is different.

But why is Xeljanz becoming more popular among doctors? In a statement to the press, analyst Ronnie Yoo, Ph.D., wrote, “Xeljanz will compete for patient share in two areas of the RA treatment [market]. First, with the non-TNF-alpha inhibitor biologics for patients who fail to respond to TNF-alpha inhibitors. Second, to a lesser degree, it has the potential to compete at the same line of therapy as the TNF-alpha inhibitors, in patients with an inadequate response to methotrexate.”